HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 5, May 2016 – Healthcare Systems & Policies in Asia       » Understanding Healthcare Policies in the Philippines: Cancer Care       » Young Innovators under 35       » Healthcare Cost Effectiveness in Singapore       » ASLAN Pharmaceuticals Opens China Office       » A Journey Inside the Human Body       » Treatment Brings New Hope for Patients Suffering From Fatal Lung Disease      
EYE ON CHINA
Chi-Med and Sinopharm form China drug distribution and marketing joint venture

Chi-Med, a pharmaceutical and healthcare company based primarily in China, has established a new joint venture with Sinopharm Group Co. Ltd. (Sinopharm). Sinopharm is the largest distributor of pharmaceutical and healthcare products and a leading value added supply chain service provider in China. The joint venture will provide distribution and marketing services to both related and third party pharmaceutical companies in China.

Chi-Med will, through a wholly-owned subsidiary, invest approximately US$9.8 million in cash into Sinopharm Holding HuYong Pharmaceutical (Shanghai) Co., Ltd. (Huyong) for the subscription of 51% of the equity in the enlarged share capital of Huyong, which will mean that Huyong will be consolidated as a Chi-Med subsidiary. The Chi-Med investment will be largely deployed for expanding future commercial activities, particularly in the area of third party drug sales and marketing.

Huyong is a Good Supply Practice (GSP) certified pharmaceutical and healthcare distribution and marketing company that was originally established in 1993 and subsequently acquired by Sinopharm in 2010. Huyong will be renamed as Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited (Hutchison Sinopharm).

Hutchison Sinopharm will provide a platform for synergy across the China Healthcare Division of Chi-Med by utilizing the services of the approximately 2,800-person prescription drug and over-the-counter drug sales teams of SHPL and HBYS. A major aspect of the Hutchison Sinopharm business strategy will be to provide sales, distribution, and marketing services to major domestic and multi-national third party pharmaceutical manufacturers. It will also provide a broadened sales and marketing platform for HHL's products and potentially the future novel drugs registered by Hutchison MediPharma Limited, Chi-Med's Drug R&D Division.

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices and Digital Health Technology
July:
Water Technology
August:
Guest Editorial - Antibody Informatics In Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy